ALSPW Spineway SAS

Reverse stock split and reduction of the share capital

Reverse stock split and reduction of the share capital

Press Release         Ecully, September 20, 20228 pm

 

Effective date of the Spineway reverse stock split

Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 40,000 old shares of 0.0001 euro par value. This transaction, which was carried out pursuant to a decision by the Company's shareholders at an Extraordinary General Meeting held on July 25, 2022, took effect on September 15, 2022.

The old Spineway shares with a par value of €0.0001 (ISIN code: FR00140072P8) were delisted from the Euronext Growth market after the close of the market on September 14, 2022 and were replaced with the new Spineway shares with a par value of €4.00 (ISIN code: FR001400BVK2) on September 15, 2022. The mnemonic code (ALSPW) remains unchanged.

It should be noted that, as of September 14, 2022, the new shares that could not be allotted individually and which correspond to fractional rights will be sold automatically by block on the market by financial intermediaries. The financial intermediaries will make the proceeds of the sale available to their shareholder clients within 30 days from September 14, 2022. For more information on the reverse split, shareholders are invited to consult the notice of reverse split published in the and available on the Company's website () and the press release published on also available on the Company's website.

Clarification on the publication of the September 12 Euronext notice

Pursuant to the publication on September 12, 2022 of a Euronext notice announcing the increase in the number of Spineway shares via the admission of 6 billion shares on September 14, 2022, Spineway wishes to clarify to its shareholders that these 6 billion shares correspond to conversions of Negma bonds carried out over the summer, on August 5 and 19, and which related to tranches of convertible bonds previously exercised. The latter were taken into consideration by the Company's account keeper in August and largely resold by Negma before the reverse stock split.

These 6 billion shares therefore have no connection with the consolidation transaction and had been admitted to trading well before September 14, 2022. During the consolidation period, i.e. between August 16 and September 14, no new tranche of convertible bonds was issued nor shares converted. Moreover, in accordance with the announcement made when its were published, Spineway would like to reiterate that it has decided to suspend the issuance of new tranches of Convertible Bonds until the end of 20221.

Reduction of the share capital

Subsequent to the reverse stock split, the Company's Board of Directors decided on September 19, 2022 to reduce the share capital by reducing the par value of the Company's shares2. This purely technical operation has no impact on the value of the Company's stock value, nor on the number of shares in circulation. Thus, after this operation, the Company's share capital is still composed of 761,848 ordinary shares, i.e. the number of shares making up the share capital following the above-mentioned reverse stock split, effective on September 15.

Upcoming:

September 28, 2022: Lyon Pôle Bourse Forum at the Palais du Commerce in Lyon

October 14, 2022: Third quarter revenues

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday - Thursday (10-12)



+33 (0)806 706 060




Eligible PEA / PME





ALSPW



Euronext Growth




AELIUM



Finance & Communication



Investor relations



Solène Kennis



 


1 As of today, 760 bonds remain to be converted out of the tranches previously raised.

2 The legal par value of one share is thus reduced from 4.00 euros to 0.05 euros and the share capital to 38,092 euros.

 

Attachment



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch